![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 22, 2014 4:11:55 PM
"Amarantus BioScience Holdings Inc. has a transformative year ahead and a diverse pipeline of promising products. Its diagnostic test for Alzheimer's disease (AD), LymPro, should be launched in H214. It will be the first blood-based test available for AD in the U.S., where there are about 0.5m people diagnosed with AD each year. Profits from LymPro could be used to develop eltoprazine and mesencephalic astrocyte-derived neurotrophic factor (MANF). . .MANF could start clinical development in 2015 and has potential in many indications."
Jason Napodano, Zacks Small-Cap Research (4/25/14) "On April 21, 2014, Amarantus Bioscience Holdings Inc. announced financial results for the year ended Dec. 31, 2013. Having spent much of the past year cleaning up the balance sheet, the company now has the financial resources to drive its assets forward in the clinic." -Zacks Small-Cap Research
The Life Sciences Report Interview with David Lowe (3/26/14) "Amarantus BioScience Holdings Ltd.'s eltoprazine molecule is now in Phase 2b for Parkinson's disease levodopa-induced dyskinesia (PD-LID), as well as attention-deficit hyperactivity disorder (ADHD). Amarantus CEO Gerald Commissiong led the charge on the negotiation front and did a brilliant job. . .
The company has been focusing on some orphan indications, such as retinitis pigmentosa (RP); it is in preclinical development with mesencephalic astrocyte-derived neurotrophic factor (MANF) in not only RP, an orphan indication, but also in Parkinson's, with some grant funding from the Michael J. Fox Foundation for Parkinson's Research. . .we believe this molecule, MANF, is one of the jewels in the field. . .we have one or two other indications for MANF, as well as the Amarantus' lead compound, eltoprazine, which is in the clinic. . . More >
Jason Napodano, Seeking Alpha (2/18/14) "Amarantus BioScience Holdings Inc. has entered into a definitive agreement with certain existing shareholders to exercise outstanding warrants that will deliver, at a minimum, $3M in new capital to the company. . .over the next few months, we expect Amarantus to put this new cash to work in several places."
Jason Napodano, Seeking Alpha (11/19/13) "We believe fundamentals are improving at Amarantus BioScience Holdings Inc., both with respect to the development of MANF (Mesencephalic-astrocyte-derived Neurotrophic Factor) and LymPro, and on the balance sheet. These improvements are the primary reasons why we believe investors should buy the stock today. . .right now the fundamentals are pointing to a potential breakout in 2014.
http://www.thelifesciencesreport.com/pub/co/6082
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM